SCHEMBL1781189

SCHEMBL1781189

CCC(=O)Nc1nc2c(s1)C(O)=C(C(=O)c1ccc(C)nc1)CC2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.38
NPC1 O15118 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MEN1 O00255 6/20 0.38
KMT2A Q03164 6/20 0.38
PI4KB Q9UBF8 1/20 0.36
TP53 P04637 1/20 0.36
LMNA P02545 3/20 0.36
MAPT P10636 3/20 0.36
KDM4E B2RXH2 2/20 0.36
HTT P42858 2/20 0.36
HPGD P15428 2/20 0.35
HSD17B10 Q99714 2/20 0.35
TSHR P16473 1/20 0.35
POLB P06746 2/20 0.35
PIK3CD O00329 1/20 0.35
PIK3CA P42336 1/20 0.35
PIK3CB P42338 1/20 0.35
PIK3CG P48736 1/20 0.35
ALDH1A1 P00352 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1117942 0.89 HTT (0.44) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL1781491 0.89 PIK3CG (0.42) RAB9ANPC1SMN1; SMN2TP53LMNA
SCHEMBL4550899 0.87 TSHR (0.40) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL1117979 0.83 PIK3CD (0.40) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL1118068 0.82 CSNK2A2 (0.38) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL1117877 0.81 POLB (0.42) RAB9ANPC1SMN1; SMN2PI4KBKDM4E
SCHEMBL1782049 0.80 PIK3CG (0.38) RAB9ANPC1SMN1; SMN2TP53LMNA
SCHEMBL1117849 0.80 HDAC1 (0.39) RAB9ANPC1SMN1; SMN2PI4KBLMNA
SCHEMBL2671316 0.79 HDAC1 (0.35) NPC1MAPTKDM4EALDH1A1HDAC1
SCHEMBL1780133 0.79 HCAR3 (0.39) RAB9ANPC1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8304556-B2 Thiazolyl-dihydro-indazoles BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-11-06 US disclosed
US-8304556-B2 Thiazolyl-dihydro-indazoles BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-11-06 US disclosed
US-20120108567-A1 Thiazolyl-Dihydro-Indazoles BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-03 US disclosed
US-20120108567-A1 Thiazolyl-Dihydro-Indazoles BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-03 US disclosed
US-20110118208-A1 Thiazolyl-Dihydro-Indazoles BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-05-19 US disclosed
US-20110118208-A1 Thiazolyl-Dihydro-Indazoles BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-05-19 US disclosed
CN-102015728-A Thiazolyl-dihydro-indazoles BOEHRINGER INGELHEIM INT 2011-04-13 CN disclosed
WO-2009112565-A1 THIAZOLYL-DIHYDRO-INDAZOLES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108567-A1 Thiazolyl-Dihydro-Indazoles MKI67, CYP11B1, IGF1R RAB9A 2207/4885NPC1 136/4885SMN1; SMN2 1428/4885
US-20110118208-A1 Thiazolyl-Dihydro-Indazoles MKI67, CYP11B1, IGF1R RAB9A 2207/4885NPC1 136/4885SMN1; SMN2 1428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.